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Background: Gastric carcinoma development is a multi-stage process that involves more than one gene. Aberrant
changes in DNA methylation are considered as the third mechanism that leads to anti-oncogene inactivation,
which plays an essential role in tumor development. In this study, we assessed the relationship among the aberrant
methylation of the promoter CpG islands of tissue inhibitor of metalloproteinase 3 (TIMP3) gene, its protein
expression, and the clinicopathological features of gastric adenocarcinoma.
Methods: The methylation status of the promoter CpG islands and the protein expression of TIMP3 gene in tumors
and adjacent normal mucosal tissues of 78 patients with gastric adenocarcinoma were detected by
methylation-specific PCR (MSP) and immunohistochemistry.
Results: The CpG island methylation of TIMP3 was detected in tumor tissues, cancer-adjacent tissues, and lymph
nodes with metastasis. In increasing order, the hypermethylation frequency of these tissues were 35.9% (28 of 78
non-neoplastic tissues), 85% (17 of 20 early-stage cases), 89.7% (52 of 58 progressive-stage cases), and 100% (78 of
78 metastatic lymph node). A marked difference was found between tumors and non-neoplastic tissues (P < 0.05),
but no difference existed among the subgroups of tumors (P > 0.05). Immunohistochemistry analysis confirmed
TIMP3 down-regulation in tumor tissues. The rate of TIMP3 gene expression was 100% in non-neoplastic tissues but
apparently decreased to various extents at different stages, i.e., decreased to 30% (6/20) at the early stage, to 3.4%
(2/58) at the progressive stage, and to 0% (0/78) in metastatic lymph nodes. Among the 70 tumor tissues with
negative TIMP3 expression, 64 (91.4%) were hypermethylated and 6 were unmethylated (8.6%), indicating a
significant association between hypermethylation and reduced or negative TIMP3 expression (P < 0.01).
Conclusion: The hypermethylation of the promoter region in CpG islands is the main mechanism of TIMP3 gene
expression and may provide evidence for the molecular diagnosis and stage evaluation of gastric cancer.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1756134016954958
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Gastric cancer (or gastric carcinoma) is one of the most
common malignancies in the world. Disease development
in gastric cancer is a multi-stage process that involves more
than one gene. Disease factors ultimately act on different
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reproduction in any medium, provided the orand expression levels that lead to the development of gas-
tric carcinogenesis. Loss of function of an anti-oncogene
may occur through various channels. In addition to dele-
tions and mutations, aberrant changes in DNA methylation
are considered as the third mechanism leading to anti-
oncogene inactivation [1,2], which plays an essential role in
tumor development. CpG islands, which are CpG-rich
sequences located in the upstream promoter region of a
housekeeping gene, are regions at which cytosine methyla-
tion does not generally occur, although stimulation by cer-
tain factors leads to its methylation. Consequently, DNA
expression is inhibited in this region [3]. The inactivation oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hMLH1, and MGMTare related to the methylation of their
respective promoter regions [4-8]. Tissue inhibitor of
metalloproteinase-3 (TIMP3) is related to tumor de-
velopment, particularly antagonizing the activity of matrix
metalloproteinases as well as inhibiting tumor growth,
angiogenesis, invasion, and metastasis [9].
In this work, we detected the methylation of the TIMP3
gene promoter CpG island and protein expression in nor-
mal gastric mucosa tissues, gastric cancer tissues, and meta-
static lymph nodes of 78 patients with gastric cancer using
methylation-specific PCR (MSP) and immunohistochemis-
try. We explored the correlation of gene promoter methyla-
tion with its corresponding protein expression and then
analyzed the relationship of TIMP3 gene CpG island abnor-
mal methylation with the development, as well as clinical
and pathological features, of gastric adenocarcinoma.
Materials and methods
Materials
All 78 cases of gastric normal tissue, gastric carcinoma,
and metastatic lymph nodes were verified by pathological
diagnosis. The tumor samples were obtained between
March 1998 to May 2005 at the First Affiliated Hospital
and Liaoning Provincial Tumor Hospital from postoperative
patients with gastric cancer (male: n = 54; female: n = 24)
with a mean age of 56.2 ± 7.5 years. Among the samples
obtained, 20 were of early gastric cancer, 58 were of
advanced gastric cancer, 44 were of differentiation, and 14
were undifferentiated. Tumor staging was based on the
International Union Against Cancer TNM staging stan-
dards, Typing of Gastric Cancer Growth Way and Statute of
Staging, and gastric cancer typing in Japan [10-12] from the
China Medical University Cancer Institute. Hydroquinone
(10 mmol/L) and sodium bisulfate (3.9 mol/L) were
purchased from Sigma. A DNA Clean-up System was
purchased from Promega. TIMP3 antibody and SP kit
were purchased from Boster Biological Engineering
Co., Ltd. (Dalian). All specimens were handled and made
anonymous according to the ethical and legal stan-
dards. The protocol was approved by the Medical Ethics
Committee of the Liaoning Provincial Tumor Hospital
and China Medical University.
MSP
In the MSP method [13], methylase processing was
conducted on normal peripheral blood cells and used
as positive controls. Untreated cells were used as negative
controls. The sequences of the methylated (TIMP3-M)
and unmethylated (TIMP3-U) primers were as follows: (1)
TIMP3-M primer sequences, 5′CGTTTCGTTATTTTTT
GTTTTTCGGTTTTC-3′ and 5′-CCGAAAACCCCGCC
TCG-3′; and (2) TIMP3-U primer sequences, 5′-TTTTG
TTTTGTTATTTTTTGTTTTTGGTTTT-3′ and 5′-CCCCCCAAAAACCCCACCTCA-3′. The PCR reaction condi-
tions were as follows: 95°C initial denaturation for 5 min,
95°C, denaturation for 30 s (40 cycles), 59°C annealing for
60s (40 cycles), 72°C extension for 60s (40 cycles), and 72°C
extension for 10 min. Agarose gel electrophoresis and
EB staining were then performed. Data from the gels
were collected with a laser density scanner (Pharmacia
LKB Ultroscan) and subsequently analyzed. All experiments
were repeated three times, and the mean value was used
for statistical analysis.
Immunohistochemistry
For immunohistochemistry, we used the streptomycesavidin–
peroxidase staining method. Immunohistochemical staining
was performed according to the manufacturer’s in-
structions. As a diagnostic criterion, the observation of
a brownish yellow cytoplasm after staining was considered
a positive result for TIMP3 expression. For the controls, a
normal tissue area was stained as the positive control, and
a normal tissue section was used as the negative control
and stained with PBS instead of a primary antibody.
Scoring standard was performed according to the method
described by Shimizu [14]. We observed the staining inten-
sity and distribution of positive cells at high magnification;
no staining was scored as 0, weak staining but significantly
stronger than the negative control was scored as 1, a clear
stain is scored as 2, and a strong stain is scored as 3. No
positive control cell is scored as 0. The required number
of positive cells, i.e., <30%, 30%–60%, and >60%, were
scored as 1, 2, and 3, respectively. Based on the total
scores, the samples were assessed for TIMP3 expression.
A score of ≤2 was classified as negative, a score of 3 was
weakly positive, a score ranging from 4 to 5 was positive,
and a score of 6 was strongly positive.
Statistical analysis
The differences among the TIMP3 gene promoter
methylation rate and protein expression of the samples
were detected and statistically analyzed by the χ2 and
Fisher methods. All data were analyzed with SPSS12
statistical software.
Results
TIMP3 gene promoter methylation analysis
Extracted genomic DNA from the sample was amplified
by MSP. The sizes of the methylated and unmethylated
PCR products were 116 and 122 bp, respectively. TIMP3
gene promoter methylation phenomenon was generally
observed in normal gastric tissues, gastric carcinoma,
and lymph node metastasis samples. The positive detection
rates were as follows: 85% (17/20) for early gastric cancer,
89.7% (52/58) for advanced gastric cancer, 98.7% (77/78)
for metastatic lymph nodes, and only 35.9% (28/78) for the
normal gastric tissue. A significant increase in TIMP3 gene
Table 1 Gastric carcinoma TIMP3 promoter methylation
and protein expression





Normal stomach 78 28(35.9) 78(100.0)
Early gastric cancer 20 17(85.0) 9(45.0)
Advanced gastric cancer 58 52(89.7) 21(36.2)
Lymph node metastases 78 77(98.7) 12(15.4)
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groups (P < 0.01; Figure 1 and Table 1), suggesting that the
methylation of TIMP3 gene may be involved in the car-
cinogenesis and metastasis of gastric cancer tumors and
metastatic lymph node tissues.
Immunohistochemistry analysis of TIMP3 protein expression
TIMP3 protein expression was positive in all 78 cases of
normal gastric tissue (100%). Among the gastric carcinoma
cases, 9 in 20 patients were positive for early gastric cancer;
11 cases were negative (55%), 21 cases were positive, and
37 were negative (63.8%) in 58 cases of advanced gastric
cancer; and 12 cases were positive and 66 cases were nega-
tive (84.6%) in 78 patients with metastatic gastric lymph
nodes. The reduced TIMP3 expression that was observed
in the gastric cancer groups was found to be statistically
significant (P < 0.01; Figure 2 and Table 1), suggesting that
TIMP3 protein expression rate decreased in gastric cancer
tumors and metastatic lymph node tissues. This reduced
expression of the gene protein may be due to the previously
observed increase in TIMP3 methylation in the gastric
cancer samples because methylation is known to suppress
protein expression. TIMP3 protein expression was mainly
located in the cytoplasm of normal glands. In a few cells, a
small amount of expression was found in the cell mem-
branes (Figure 2). In the normal gastric mucosal cells, no
glandular structure destruction was observed and coloring
was not significantly reduced. The early gastric cancer
glands showed structural damage and weak cancer cell
coloring. The advanced gastric cancer tissues showed large
areas of massive growth (undifferentiated carcinoma) and,
apart from the individual cells, the rest were not colored.
Relationship between TIMP3 gene promoter methylation
and TIMP3 protein expression
In the advanced gastric cancer group, the rate of TIMP3
methylation was significantly higher than the lumpish
and nested growing tissues (100% vs. 77.8%, respectively;
P < 0.01). The TIMP3 methylation rate in metastatic lymph
nodes in the ≥7 tissue group was significantly higher than
the <7 tissue group (100% vs. 83.3%, respectively; P < 0.05).
The subserosal and serosal tissue group was significantlyFigure 1 Methylation-specific PCR (MSP): 1, normal control
(normal gastric tissue); 2, early gastric cancer; 3, advanced gastric
cancer; 4, transfer of lymph node. M, Marker DL2000; m, Methylation
amplification fragment; u, unmethylation amplification fragment.higher than the submucosal and myometrium tissue group
(91.3% and 96.6% vs. 50%, respectively; P < 0.05). Increased
TIMP3 gene methylation rate was generally observed
in diffuse-like growth, lymph node metastases (≥7),
and subserosal and serosal tumors, implying that no
relationship existed between TIMP3 gene methylation
and tumor size, macroscopic type, and histological
type. The positive rate of the 58 cases of advanced gastric
cancer tissues was 36.2% (21). TIMP3 protein expression in
massive and nested growing tissues was significantly higher
than that of diffuse-like growth tissues (55.6% vs.19.4%,
respectively; P < 0.01). TIMP3 protein expression in the
metastatic lymph node ≥7 tissues was significantly higher
than the <7 tissue (47.2% vs. 18.2%, respectively; P < 0.05)
(Table 2). These results suggested that decreased TIMP3
protein expression rate was more common in diffuse-like
growth and lymph node metastatic (≥7) tumors, but
reduced expression was not related to tumor size, gross
type, histological type, and depth of invasion.
Discussion
The formation of malignancy is multi-factorial and occurs
in multiple stages. The biological characteristics of malig-
nant tumors include invasive growth and metastasis. TheFigure 2 TIMP3 protein immunohistochemisty (SP 400×):
a, normal gastric tissue; b, early gastric cancer; c, advanced
gastric cancer; d, transfer of lymph node.
Table 2 Relationship between advanced gastric cancer pathology TIMP3 methylation and its protein expression level
Index n TIMP3 promoter methylation TIMP3 protein tumor size
Tumor size (cm) <5 5 3 (60.0) 1 (20.0)
5 − 10 45 42 (93.3) 18 (40.0)
>10 8 7 (87.5) 2 (25.0)
General types Borr.2 12 10 (83.3) 4 (33.3)
Borr.3 37 33 (89.2) 15 (40.5)
Borr.4 9 9 (100.0) 2 (22.2)
Histological differentiation Differentiated 44 39 (88.6) 17 (38.6)
Undifferentiated 14 13 (92.9) 4 (28.6)
Growth pattern Clumps + nested 27 21 (77.8) 15 (55.6)
Diffuse-like 31 31 (100.0) b 6 (19.4) b
Lymph node metastasis <7 36 30 (83.3) 17 (47.2)
≥7 22 22 (100.0) a 4 (18.2) a
Infiltration Submucosal muscularis 6 3 (50.0) 1 (16.7)
Subserosal 23 21 (91.3) a 9 (39.1)
Serosa 29 28 (96.6) 11 (37.9)
a P < 0.05, b P < 0.01.
Guan et al. Diagnostic Pathology 2013, 8:110 Page 4 of 6
http://www.diagnosticpathology.org/content/8/1/110mechanism behind tumor development involves abnormal
changes in gene structure and function in the interior of
the cell. Modern theorists consider that the process of
tumor formation comprises two major mechanisms: the
first one is at the genetic level, i.e., gene mutation causes
DNA nucleotide sequence changes; and the second one is
at the epigenetic level. Previous studies have focused on
changes in gene expression that are inherited through
meiosis and do not involve a change in DNA sequence
but affect the expression and gene regulating function of
DNA, mainly by chemical modification. This mechanism
is gaining increased attention from researchers of tumor
formation processes [15,16].
In the DNA of tumor tissues, abberant methylations
are often observed in gene promoter regions, including
hypomethylation in the oncogene. This gene is closely
related to cell proliferation cycle and hypermethylation
in tumor suppressor genes. These abnormal methylation
changes can activate oncogenes [17-19] and inhibit the
mRNA transcription of tumor suppressor genes [20],
leading to gene inactivation. Aberrant methylation in
DNA occurs through the presence of highly methylated
CpG islands in the 5′ end of a promoter control region.
The TIMP family has four protein members: TIMP-1, 2, 3,
and 4. TIMP-1, 2, and 4 are soluble secretory proteins. By
contrast, TIMP-3 is a non-soluble protein that combines
with the extracellular matrix, is located in the outer cell
membrane [21], and can be closely connected with the
basilar membrane. The function of TIMPs is the inhibition
of tumor necrosis factor-α (TNF-α)-converting enzymes
and the induction of programmed cell death through the
stable cell surface TNF-α receptor [22]. The induction ofapoptosis through TIMP occurs by two pathways: MMP
dependent and independent. Although TIMP-3 and 4 have
a high affinity for MMP-2, the proteins effectively inhibit
MT1-MMP, thereby activating the MMP-2 zymogen
process and inhibiting tumor cell growth and metastasis.
Smith et al. [23] found that the expression of TIMP-3 in
human colon cancer cell lines are rare in mitosis. Most cells
are arrested in the G1 phase, although the application of
TNF-α antibody decreases mitotic arrest by 70%.
To explore the relationship between TIMP3 and gastric
cancer, as well as its mechanism in gastric inactivation, we
detected TIMP3 gene 5′ CpG island hypermethylation in
normal gastric mucosa, gastric carcinoma, and metastatic
lymph nodes. We found that in >85% of all gastric cancer
tissues, the TIMP3 gene 5′ CpG island exhibited aberrant
methylation that was significantly higher (P < 0.01) than
that of the normal gastric tissue group, which implied that
TIMP3 gene promoter CpG island methylation reduced
TIMP3 gene expression and was thus the main tumor
suppressor-inactivation mechanism in gastric cancer.
Gagnon et al. [24] reported that in all MCF-7 lung cancer
cell lines with TIMP3 mRNA expression loss and TIMP3
gene promoter CpG island methylation, demethylation
was induced by 5-AZA-CdR. TIMP3 expression before
and after 5-AZA-CdR induction was assessed by RT-PCR,
which showed that demethylation resulted in TIMP3 gene
re-expression, consistent with our results.
In the present study, all 78 cases of normal gastric tissue
were positive for TIMP3 protein expression. Among these
78 cases, only 28 (35.9%) were positive for methylation.
Among the 20 patients with early gastric cancer, 9 were
positive for TIMP3 protein expression and 17 (85%) were
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gastric cancer, 21 were positive for TIMP3 protein expres-
sion and 52 (89.7%) were positive for methylation. Among
the 78 cases of metastatic lymph nodes, 12 were positive
for TIMP3 protein expression and 77 cases (98.7%) were
positive for methylation. Increased methylation rate was
significant among the early cancer, advanced cancer, and
metastatic lymph node samples compared with normal
tissue samples (P < 0.01), confirming that the loss of TIMP3
protein expression was closely related to TIMP3 gene pro-
moter CpG island methylation. Feng HF et al. [25] reported
the same results in JAR and JEG-3 choriocarcinoma cell
lines. Therefore, our study confirmed that TIMP3 gene
promoter CpG island methylation was the main reason for
the reduced TIMP3 protein expression in gastric cancer.
Among the 58 advanced gastric cancer samples, 52
were positive for TIMP3 promoter CpG island methylation
and 21 were positive for TIMP3 protein expression. This
finding suggested that apart from CpG island methylation,
other factors such as genetic variation caused the absence
of TIMP3 gene expression. In our experiments, 34 samples
were positive for methylation, and unmethylation was
usually interpreted as follows: incomplete methylation
status of genes may exist, and if the tumor tissue is
mixed with non-tumor cells, a positive PCR product
for unmethylation (by MSP with unmethylated primer)
may be observed. TIMP3 protein expression of the
sample was negative, so these samples were defined as
methylation positive.
In China, the 5-year survival rate of gastric carcinoma
patients is only about 40% after resection. The poor
prognosis is associated with extensive local invasion and/or
regional lymph node metastasis [26]. Local recurrence
remains as a major cause of cancer-related deaths after
resection in gastric cancer patients [27]. Therefore, reliable
criteria for the prediction of recurrence and identification
of tumors must be established to understand molecular and
cellular processes, as well as discover new and possible
therapeutic molecular targets [28].
Kerbel [29] reported that subcloning tumor cells with
metastatic potential have a growth advantage in the early
stage of primary foci. The reason for such growth advan-
tage is that the metastatic subclone cell population may
secrete a particular factor or local cell growth factor,
thereby causing a special reaction that results in selective
growth. Detection of molecular marker levels in primary
tumor specimens may reflect the general metastatic char-
acteristics of the whole tumor. In this group, the methyla-
tion rates were only 35.9% for the normal gastric tissues,
85% and 89.7% for the early and advanced cancers, re-
spectively, 98.7% for metastatic lymph nodes. Consistently
high TIMP3 protein expression was observed only in
normal gastric tissues. Early and advanced gastric cancers
exhibited focal weak expression, and metastatic lymphnodes showed almost no positive expression. This finding
suggested that TIMP3 methylation increased with tumor
progression and that protein expression gradually de-
creased. Consequently, the metastatic potential and growth
advantage of cells gradually increased, ultimately resulting
in metastasis. Yegnasubramanian et al. [30] reported that
tumor metastasis was related to TIMP3 methylation in
prostate cancer cell lines as revealed by the real-time MSP
of samples from 73 patients with early prostate cancer, 91
patients with metastatic prostate cancer, and 25 cases with
prostatic tissue. This result implied a relationship between
CpG methylation and the grading and progress of prostate
cancer. TIMP3 gene methylation reportedly plays an
important role in the metastatic process, and the detection
of TIMP3 CpG methylation has some practical value in
predicting the metastatic potential of the primary tumor.
TIMP3 has a high frequency of genetic variation in many
types of human malignant tumors, including mutations,
deletions, methylation, chromosomal translocation, and so
on [31]. These mutations result in the loss of the normal
function of a tumor suppressor gene, namely, the inhibition
of cell proliferation (i.e., gene inactivation) and are closely
related to the development of cancer [32]. However, few
studies have been conducted on TIMP3 gene modification
in primary gastric cancer, and the results of these studies
show discrepant results from a low gene deletion rate to no
mutation at all. Accordingly, other inactivation mechanisms
of gastric cancer involving TIMP3 gene have been investi-
gated [33]. Thus, the complexity of tumor pathogenesis is
not only a reflection of genetic change by mutation or dele-
tion but also a reflection of epigenetic alterations, such as
DNA methylation. An in-depth study of the relationship
between DNA methylation and gene expression, as well as
its corresponding mechanism, is recommended because the
results can guide the clinical treatment of cancer.
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